公开(公告)号：WO2019113132A1

公开(公告)日：2019-06-13

申请号：PCT/US2018/063941

申请日：2018-12-04

Applicant: CARIBOU BIOSCIENCES, INC.

Inventor： STENGEL, Katharina

IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/88 ,  C12N15/113

CPC classification number: C07K14/7158 ,  A61K35/17 ,  C07K16/2803 ,  C12N5/0636 ,  C12N15/111 ,  C12N15/88 ,  C12N2310/20 ,  C12N2506/115 ,  C12N2510/00 ,  C12N2740/16043

Abstract: Modified lymphocytes that ectopically express an endogenous gene of interest, such as a gene encoding a chemokine cell surface receptor, are described. Also described are methods of producing the lymphocytes by delivery of transcriptional activator complexes, as well as methods of targeting cells with cognate chemokines, in order to treat various disorders.

公开(公告)号：WO2017064222A1

公开(公告)日：2017-04-20

申请号：PCT/EP2016/074644

申请日：2016-10-14

Applicant: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN

Inventor： KOBOLD, Sebastian ,  ENDRES, Stefan ,  RAPP, Moritz ,  GRASSMANN, Simon

IPC: C12N15/85 ,  C12N15/867 ,  C07K14/715 ,  C12N5/16 ,  A61K35/17

CPC classification number: C12N15/86 ,  C07K14/7158 ,  C12N2740/13043

Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) γδ T cell(s) or (a) natural killer (NK) T cell(s)for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.

Abstract translation: （a）CD8 + T细胞，（a）CD4 + T细胞，（a）CD3 + T细胞， T细胞，（a）用于靶向肿瘤治疗的γδT细胞或（a）自然杀伤（NK）T细胞，核酸序列，能够转导这样的（a）T细胞的载体 ），（a）携带本发明的核酸序列或载体的转导的T细胞，包含本发明的核酸序列或载体的方法和试剂盒。 本发明还提供了所述转导的T细胞在用于治疗以CXCL16过表达为特征的疾病的方法中的用途，以及药物组合物/药物，其包含（a）表达CXCR6的转导的T细胞用于 治疗以CXCL16过度表达为特征的疾病的方法。

公开(公告)号：WO2017023803A1

公开(公告)日：2017-02-09

申请号：PCT/US2016/044858

申请日：2016-07-29

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA ,  INTIMA BIOSCIENCE, INC.

Inventor： MORIARITY, Branden ,  WEBBER, Beau ,  MCIVOR, Scott, R. ,  LARGAESPADA, David ,  CHOUDHRY, Modassir

IPC: A61K35/00 ,  A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  C07H21/04 ,  C07K14/725

CPC classification number: A61K35/17 ,  C07K14/4718 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7158 ,  C12N5/0636 ,  C12N9/22 ,  C12N9/96 ,  C12N15/113 ,  C12N15/87 ,  C12N15/907 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80 ,  Y02A50/463

Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

Abstract translation: 公开了用于治疗癌症的转基因组合物，例如非病毒载体和T细胞。 还公开了制备和使用转基因组合物治疗癌症的方法。

公开(公告)号：WO2016130899A1

公开(公告)日：2016-08-18

申请号：PCT/US2016/017714

申请日：2016-02-12

Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Inventor： ACKERMAN, Steven, J. ,  LAFFEY, Fan, Gao ,  HITCHINSON, Ben ,  GARNIER, Boris ,  GAPONENKO, Vadim ,  TARASOVA, Nadya ,  ABDELKARIM, Hazem

IPC: A61K38/04 ,  C07K14/715 ,  A61K38/00

CPC classification number: A61K38/195 ,  A61K9/008 ,  A61K38/00 ,  A61K47/10 ,  A61K47/6813 ,  A61P11/06 ,  A61P37/08 ,  C07K14/4703 ,  C07K14/521 ,  C07K14/7158

Abstract: A C-C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3 -mediated disease or condition.

Abstract translation: 提供了通过结合并抑制配体介导的信号传导和趋化性同时促进CCR3的内化和降解而显示偏向拮抗作用的CC趋化因子受体3（CCR3）肽类似物，其是使用肽类似物来治疗，预防或 改善一种或多种嗜酸性粒细胞或CCR3介导的疾病或病症的症状。

公开(公告)号：WO2015167766A1

公开(公告)日：2015-11-05

申请号：PCT/US2015/024876

申请日：2015-04-08

Applicant: SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)

Inventor： WAGNER, Thor ,  RAWLINGS, David, J. ,  SCHARENBERG, Andrew, M. ,  SATHER, Blythe ,  SAHNI, Jaya

IPC: C12N15/00 ,  C12N5/071

CPC classification number: C07K16/1054 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K14/7158 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/81 ,  C12N5/0636 ,  C12N9/22 ,  C12N2510/00

Abstract: The present application generally relates to methods of genetically modifying a T-cell comprising a chimeric antigen receptor wherein the T-cell lacks a co-receptor for HIV. The application further relates to methods of making a nucleic acid encoding a chimeric antigen receptor, nucleic acids encoding a chimeric antigen receptor, and genetically modified T-cells comprising a chimeric antigen receptor disclosed herein. The application further relates to methods of treating, inhibiting, or ameliorating HIV in a subject including administering to the subject a cell disclosed herein.

Abstract translation: 本申请通常涉及遗传修饰包含嵌合抗原受体的T细胞的方法，其中T细胞缺少HIV共同受体。 本申请还涉及制备编码嵌合抗原受体的核酸，编码嵌合抗原受体的核酸和包含本文公开的嵌合抗原受体的遗传修饰的T细胞的方法。 本申请还涉及在受试者中治疗，抑制或改善HIV的方法，包括向受试者施用本文公开的细胞。

公开(公告)号：WO2014201308A1

公开(公告)日：2014-12-18

申请号：PCT/US2014/042204

申请日：2014-06-12

Applicant: WASHINGTON UNIVERSITY

Inventor： ARBEIT, Jeffrey ,  CURIEL, David

IPC: C12N15/861 ,  C12N15/66 ,  C07K7/06 ,  C07K14/71 ,  C07K14/715 ,  A61K48/00

CPC classification number: C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/71 ,  C07K14/715 ,  C07K14/7158 ,  C07K2319/32 ,  C07K2319/735 ,  C12N7/00 ,  C12N9/78 ,  C12N2710/10321 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/002 ,  C12N2830/003 ,  C12N2830/008 ,  C12Y305/04001 ,  Y02A50/475

Abstract: Disclosed are adenovirus vectors comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric AD5-T4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (MBP), and a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are methods of expressing a transgene in an endothelial cell in vivo, comprising administering to a mammal an adenovirus comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are uses of the adenoviral vectors, including mobilization of granulocytes, monocytes and lymphocytes from bone marrow, mobilization of cancer cells in vivo, selective targeting of endothelial cells, and cancer treatment methods.

Abstract translation: 公开了包含可操作地连接到转基因的ROBO4增强子/启动子的腺病毒载体。 还公开了包含嵌合AD5-T4噬菌体纤维蛋白轴，显示骨髓细胞结合肽（MBP）的三聚体结构域和可操作地连接到转基因的ROBO4增强子/启动子的腺病毒载体。 还公开了在体内在内皮细胞中表达转基因的方法，包括向哺乳动物施用包含可操作地连接到转基因的ROBO4增强子/启动子的腺病毒。 还公开了腺病毒载体的使用，包括从骨髓中移动粒细胞，单核细胞和淋巴细胞，体内移动癌细胞，选择性靶向内皮细胞和癌症治疗方法。

公开(公告)号：WO2014186842A1

公开(公告)日：2014-11-27

申请号：PCT/AU2014/050048

申请日：2014-05-22

Applicant: MONASH UNIVERSITY

Inventor： MACKAY, Charles Reay ,  ROBERT, Remy Michel

IPC: C07K16/28 ,  A61K39/395 ,  C07K7/04 ,  C07K14/705 ,  A61K31/436 ,  A61K38/20 ,  A61P37/06

CPC classification number: A61K31/436 ,  A61K38/13 ,  A61K38/2013 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/7158 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/34 ,  A61K2300/00

Abstract: Provided herein are, inter alia , antibodies that specifically bind to epitopes within the inflammatory chemokine receptor CXCR3, and methods of using the antibodies. In exemplary embodiments, provided herein are antibodies and antigen-binding fragments thereof that specifically bind to an epitope within amino acid residues 23 to 44 of the human CXCR3 set forth in SEQ ID NO:4, or within corresponding amino acid residues in another CXCR3 polypeptide.

Abstract translation: 特别地，本文提供特异性结合炎症趋化因子受体CXCR3内的表位的抗体以及使用抗体的方法。 在示例性实施方案中，本文提供了特异性结合SEQ ID NO：4所示的人CXCR3的氨基酸残基23至44内的表位的抗体及其抗原结合片段，或其它CXCR3多肽中相应的氨基酸残基 。

公开(公告)号：WO2013107905A1

公开(公告)日：2013-07-25

申请号：PCT/EP2013/051041

申请日：2013-01-21

Applicant: VIB VZW ,  VRIJE UNIVERSITEIT BRUSSEL ,  UNIVERSITEIT GENT

Inventor： STEYAERT, Jan ,  CALLEWAERT, Nico ,  LAEREMANS, Toon ,  PARDON, Els ,  VANDEWALLE, Kristof ,  CLAES, Katrien

IPC: C07K14/705 ,  C07K14/72 ,  C12N1/15 ,  C12N1/21 ,  C12N5/10

CPC classification number: C07K16/2866 ,  C07K14/705 ,  C07K14/7158 ,  C07K14/723 ,  C07K2317/569 ,  C12N15/815 ,  C12N15/85 ,  G01N33/5041 ,  G01N33/6863 ,  G01N2333/7158 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2500/20

Abstract: The present invention relates cells or cellular systems that express both a membrane protein and a binding domain directed to said membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of said membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.

Abstract translation: 本发明涉及表达膜蛋白和指向所述膜蛋白的结合结构域的细胞或细胞系统。 此外，提供了使用这样的细胞或细胞系统产生更高量的所述膜蛋白的方法。 此外，细胞或细胞系统可用作膜蛋白的结构和功能表征的工具，以及靶向膜蛋白的筛选和药物发现工作。

公开(公告)号：WO2012159120A2

公开(公告)日：2012-11-22

申请号：PCT/US2012/038901

申请日：2012-05-21

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. ,  CHANG, Lung-ji

Inventor： CHANG, Lung-ji

CPC classification number: A61K48/005 ,  C07K14/7158 ,  C12N15/1132 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/31

Abstract: Disclosed herein are methods and compositions for treating or increasing resistance HIV infection. Vectors carrying a codon-optimized CCR5delta32 gene, Hl-promoter driven CCR5shRNA and/or a triple miRNA (microRNA) intronic cassette (miR155, 19a, 30a) against HIV-1 pol, int and vpu may be packaged into virus particles. In a specific embodiment, vectors carrying the CCR5shRNA and the triple miRNA against HIV-1, pol, int and vpu without the CCR5delta32 gene are provided. Significant resistance to HIV-1 infection and envelope mediated fusion was observed in the vector-modified HOS-R5 cells that endogenously express CD4, CCR5 and CXCR4. Expression of endogenous CCR5 was inhibited more than 90% after vector CCR5shRNA gene transfer as demonstrated by flow cytometry.

Abstract translation: 本文公开了用于治疗或增加抗性HIV感染的方法和组合物。 载有密码子优化的CCR5delta32基因，启动子驱动的CCR5shRNA和/或针对HIV-1 pol，int和vpu的三重miRNA（microRNA）内含子盒（miR155,19a，30a）的载体可以包装到病毒颗粒中。 在具体实施方案中，提供携带CCR5shRNA和针对HIV-1，pol，int和vpu而没有CCR5delta32基因的三重miRNA的载体。 在内源表达CD4，CCR5和CXCR4的载体修饰的HOS-R5细胞中观察到对HIV-1感染和包膜介导融合的显着抗性。 内源性CCR5的表达在载体CCR5shRNA基因转移后被抑制超过90％，如流式细胞术所证实的。

公开(公告)号：WO2012109314A2

公开(公告)日：2012-08-16

申请号：PCT/US2012/024265

申请日：2012-02-08

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  LIWANG, Patricia ,  ZHAO, Bo

Inventor： LIWANG, Patricia ,  ZHAO, Bo

CPC classification number: C07K14/7158 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/74 ,  C12N2740/15033 ,  C12N2740/16122

Abstract: The present disclosure provides chimeric polypeptides comprising a CCR5-binding protein and a gp41-binding protein and methods of using these chimeric polypeptides or related compositions to prevent or treat HIV infection.

Abstract translation: 本公开提供了包含CCR5结合蛋白和gp41结合蛋白的嵌合多肽和使用这些嵌合多肽或相关组合物来预防或治疗HIV感染的方法。